@FierceBiotech: Zymeworks bags a $61.5M round, with a merger on tap and an IPO in view. Report | Follow @FierceBiotech
@JohnCFierce: Mylan bets $245M on a 50/50 biosimilar development pact with Momenta. Story | Follow @JohnCFierce
@DamianFierce: I feel like Bill Gross trying to get people to rise up against Bill Gross. More | Follow @DamianFierce
> Former Melinta Therapeutics CEO Mary Szela is taking the CEO spot at Aegerion Pharmaceuticals ($AEGR), taking over for former chief Marc Beer, who resigned last year. News
> Pfizer ($PFE) is partnering with Adaptive Biotechnologies in hopes of using genomic sequencing to better match cancer patients to in-development immunotherapies. More
> U.K. biotech investor Neil Woodford has again called for GlaxoSmithKline ($GSK) to break up its business. Story
Medical Device News
@FierceMedDev: Bard to close Minnesota plant, eliminating 185 jobs. Article | Follow @FierceMedDev
@EmilyWFierce: $GSK halting speakers fees for docs in an effort to clean up its tarnished rep. More from the FT | Follow @EmilyWFierce
@VarunSaxena2: ICYMI: NEA partner outlines challenging med tech VC landscape heading into 2016. Article | Follow @VarunSaxena2
> Sony, Fujifilm reportedly considering bidding for Toshiba's $3B+ imaging device unit. More
> Validic app enables remote medical device data capture via smartphone camera. Report
> Michael J. Fox Foundation and Cynapsus team for wearable device study for Parkinson's. Article
Pharma News
@FiercePharma: China Animal Healthcare creates embarrassment for stakeholder Lilly. FierceAnimalHealth story | Follow @FiercePharma
@EricPFierce: ICYMI: 18 months after the FDA slapped Cadila with a Form 483, it sends a warning letter. More | Follow @EricPFierce
@CarlyHFierce: If hospitalized Valeant chief makes an exit, it'll be without a golden parachute. More | Follow @CarlyHFierce
> U.K. investor Woodford calls again for breakup of 'complicated' GSK. Story
> Wait for it--Shire could finally announce $32.5B Baxalta deal by Monday. Item
> Aegerion names Mary Szela CEO to replace controversial, and overly talkative, Marc Beer. Article